Skip to content

Study on Efficacy and Safety of Non-invasive Neuromodulation Therapy for Essential Tremor

Study on Efficacy and Safety of Non-invasive Neuromodulation Therapy for Essential Tremor

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118885
Enrollment
Unknown
Registered
2026-02-12
Start date
2026-02-16
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Essential tremor

Interventions

Essential tremor group:Transcutaneous afferent patterned stimulation(TAPS)

Sponsors

Beijing Friendship Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >=18 years and =2 on at least one primary hand task in the clinical assessment of the Tremor Evaluation Scale for Idiopathic Tremor (TETRAS), and >=3 on the self-reported Bain & Findley Activities of Daily Living Scale (BF-ADL); 4. Willingness to sign an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Implanted brain or cardiac pacemakers; 2. History of thalamotomy; 3. Epilepsy; 4. Current botulinum toxin treatment for hand tremor; 5. Upper limb skin tumors or hemangiomas; 6. Neurological lesions in the study upper limb; 7. Known allergy to any component of the device (e.g., silicone, cotton textiles); 8. Pregnant women; 9. Caffeine intake or excessive alcohol consumption within 8 hours prior to enrollment; 10. Patients with concomitant severe cardiovascular disease or other neurological disorders; 11. Patients unable to comply with follow-up requirements; 12. Patients deemed unsuitable for this clinical trial by the investigator; 13. Patients meeting any of the following criteria may withdraw from the study: (1) Patients experiencing any adverse events during treatment; (2) Patients unable to use the device as required by the investigator on a daily basis; (3) Patients using other tremor treatment methods during participation in this study; (4) Patients who voluntarily decide not to continue participating in the study; (5) Patients deemed unsuitable for continued participation in this clinical trial by the investigator; (6) Patients with a history of regular medication for essential tremor who have undergone medication adjustments within one month prior to enrollment.

Design outcomes

Primary

MeasureTime frame
Tremor Research Group Essential Tremor Rating Scale (TETRAS);Tremor Power (Tremor Amplitude and Frequency);

Secondary

MeasureTime frame
Bain & Findley Activity of Daily Living;Hamilton Anxiety Scale(HAMA);

Countries

China

Contacts

Public ContactHongyan Bi

Beijing Friendship Hospital Affiliated to Capital Medical University

hybi1996@sina.com+86 130 5166 6369

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026